TTRX

$3.62

Post-MarketAs of Mar 17, 8:00 PM UTC

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.62
Potential Upside
5%
Whystock Fair Value$3.80
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chron...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$106.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-2324.83%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.34

Recent News

MarketBeat
Mar 2, 2026

Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy

Turn Therapeutics (NASDAQ:TTRX) executives outlined the company’s focus on inflammatory skin disease and provided updates on its lead topical candidate, GX-03, during a presentation at an Oppenheimer-hosted event. CEO and founder Bradley Burnam, joined by CFO Zuraiz Chaudhary, emphasized the company

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Feb 4, 2026

Positive Signs As Multiple Insiders Buy Turn Therapeutics Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 8, 2026

Great week for Turn Therapeutics Inc. (NASDAQ:TTRX) insiders who have 59% stake and they haven’t stopped buying

Key Insights Significant insider control over Turn Therapeutics implies vested interests in company growth Bradley...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
24/7 Wall St.
Dec 29, 2025

Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More

Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower on Friday, with the venerable S&P 500 taking early bows as it hit a fresh all-time high, joining the Dow Jones Industrial Average ... Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.